Bardoxolone Methyl Suppressed Colorectal Cancer Cells In Vitro by Inhibiting the PI3K Signaling Pathway

The authors investigated bardoxolone methyl (CDDO-Me), a synthetic triterpenoid, as a potential therapeutic agent for colorectal cancer (CRC). Integrating network pharmacology, bioinformatic analyses, and in vitro assays, they evaluated the effects of CDDO-Me on CRC cells.